Quantifying the Value of Flexibility from Continuous Manufacturing of Drug Products

15:35 - 16:10

The benefits derived from Continuous Manufacturing of drug products span the product development life cycle, from rapid experimentation and facile scale up, to site tech transfer, flexible batch sizes and automated digital manufacturing. Despite the broad benefits, efforts to quantify the value of continuous manufacturing have been difficult, as much of the value is realized when flexibility is used in reaction to a changing landscape - a situation not often included in business case analyses. We attempt to quantify the value of flexibility obtained through continuous manufacturing by a novel method of analysis, backed by data obtained from Merck’s first product manufactured by this route.

Robert Meyer, Head of Innovation Technology Group, Pharmaceutical Commercialization, Merck